Business
Transfer of certain SkinBioTherapeutics plc shares
Transfer of certain SkinBioTherapeutics plc shares.
About this update from Optibiotix Health Plc
[{"type":"text","content":"\n \nRNS Number : 0909H OptiBiotix Health PLC 29 July 2019 \n\nOptiBiotix Health plc\n(\"OptiBiotix\" or the \"Company\")\n \nTransfer of certain SkinBioTherapeutics plc shares\n \nOptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that a portion of its shareholding in SkinBioTherapeutics plc consisting of 20,438,496 ordinary shares representing 15.88% of SkinBioTherapeutics plc's total issued share capital, have been dematerialised and transferred to a nominee CREST account (Pershing Nominees). OptiBiotix plc remains the beneficial owner of the transferred 20,438,496 ordinary shares.\n \nThere has been no change in the Company's overall beneficial holding of its SkinBioTherapeutics plc shareholding which in total consists of 49,794,190 representing 38.9% of SkinBioTherapeutics plc's total issued share capital.\n \nThis announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.\n \nFor further information, please contact:\n \n \n\n\n\nOptiBiotix Health plc\n\n\nwww.optibiotix.com\n\n\n\n\nStephen O'Hara, Chief Executive\n\n\nContact via Walbrook below\n\n\n\n\n\n\n\n\n\n\n\n\nCairn Financial Advisers LLP (NOMAD)\n\n\n\n\n\n\n\nLiam Murray / Jo Turner / Ludovico Lazzaretti\n\n\nTel: 020 7213 0880\n\n\n\n\n \nfinnCap (Broker)\n\n\n\n\n\n\n\nGeoff Nash / Kate Bannatyne (Corporate Finance)\n \n\n\n \nTel: 020 7220 0500\n\n\n\n\nCamille Gochez (Corporate Broking)\n\n\n \n\n\n\n\n\n\n\n \n\n\n\n\ngoetzpartners securities Limited\n\n\nTel: 0203 859 7725\n\n\n\n\nUlrich Kinzel \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nWalbrook PR Ltd\n\n\n\n\n\n\n\nAnna Dunphy\n\n\nMob: 07876 741 001\n\n\n\n\n\n\n\n\n \nAbout OptiBiotix - www.optibiotix.com \n \nOptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.\n \nOptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formula...